|
- OPDIVO® (nivolumab)
OPDIVO® (nivolumab) is a prescription medication that treats certain types of cancer Read the indications, side effects, and more Please see Indication and Important Safety Information
- How This Treatment Works | OPDIVO® (nivolumab)
Learn how OPDIVO® (nivolumab) alone and OPDIVO® + YERVOY® (ipilimumab) in combination work with your immune system to fight cancer Ask your doctor if these immunotherapies may work for you Access treatment information for your cancer type
- OPDIVO ® with You
Sign up for OPDIVO with You, a support program that offers helpful information if you are about to start or are currently on OPDIVO® (nivolumab) or an OPDIVO®-based combination Please see Indication and Important Safety Information
- Financial Information: Cost, Access Affordability - OPDIVO
Important Facts About OPDIVO ® (nivolumab) and OPDIVO + YERVOY ® (ipilimumab) This is a summary of important information that you need to know about OPDIVO and OPDIVO + YERVOY Your healthcare team can work with you to help answer any questions you may have about these medications
- 2. 1. 8. 1 Advanced Colorectal Cancer (MSI-H dMMR) | Clinical Trial . . .
See how OPDIVO® (nivolumab) + YERVOY® (ipilimumab) performed in a clinical trial for certain patients 12 years of age and older with advanced MSI-H dMMR colorectal cancer that has spread or grown Please see Indication and Important Safety Information
- Clinical trial results for - OPDIVO
See how OPDIVO® (nivolumab) performed in a clinical trial as a treatment for certain adults with previously treated advanced bladder or urinary tract cancer, or urothelial carcinoma Please see Indication and Important Safety Information
- Patient and Caregiver Stories | OPDIVO® (nivolumab)
Watch videos of real OPDIVO® (nivolumab) patients and caregivers Learn more about patients' diagnoses and treatment experiences Please see Indication and Important Safety Information
- Advanced Kidney Cancer | Clinical Trial Results | OPDIVO® (nivolumab . . .
See how OPDIVO® (nivolumab) + CABOMETYX® (cabozantinib) performed in a clinical trials for adults with previously untreated kidney cancer that has spread (advanced renal cell carcinoma or aRCC) Please see Indication and Important Safety Information
|
|
|